Pageviews:
Introduction
If you grew up in India, there is a good chance you can hum the Nirma jingle from memory. “Washing powder Nirma, washing powder Nirma, Nirma!” That catchy tune sold millions of Indian households on a cheap, phosphate-free detergent made by a Gujarati chemist named Karsanbhai Patel, who started the whole thing in the 1970s because he thought Hindustan Lever’s Surf packets were simply too expensive for ordinary people. Today, that same company is making headlines for something very different. In September 2023, Nirma bought a 75% stake in a listed pharmaceutical company called Glenmark Life Sciences, and then launched an open offer to pick up a further 17% from public shareholders. The soap maker wants to be a pharma player, and the business logic behind that decision turns out to be more interesting than the jingle.
What Exactly Did Nirma Buy
Glenmark Life Sciences, or GLS as people in the industry call it, is not a company that sells medicine you pick up at a pharmacy. It makes what are called Active Pharmaceutical Ingredients, or APIs, which are the raw chemical compounds that every drug contains. Think of an API as the flour inside a loaf of bread, the finished product cannot exist without it. GLS has built a strong position in APIs used to treat chronic conditions like heart disease, neurological disorders, diabetes, and pain, and those four segments together make up over 60% of its revenues. Because drugs for chronic illness are taken regularly and cannot easily be swapped for cheaper alternatives, the companies that make these APIs can charge better prices, which is why GLS reports an EBITDA margin of around 30% compared to an industry average of just 19%.
Why This Business Is Worth Wanting
The numbers that really stand out are around market share. GLS controls over 30% of the global market in several key drug ingredients, which means it has genuine pricing power rather than being squeezed by competition on every side. On top of that, the Indian government has been actively pushing domestic companies to manufacture more APIs at home, since India currently imports 70 to 80% of its API requirements from China. Government incentives designed to bring that manufacturing back to Indian soil could directly benefit a company like GLS, making the investment look even more attractive for Nirma going forward. GLS has also recently moved into oncology APIs, which are used in cancer treatment and carry some of the highest margins in the entire industry.
The Glenmark Life Sciences Story
Glenmark Life Sciences started its life as the internal API supplier for its parent company, Glenmark Pharma. Glenmark Pharma had built its business on generic drugs, the kind that are copies of existing medicines whose patents have expired, and it wanted to control the cost of its raw materials by making them in house. But Glenmark Pharma eventually decided that its future lay in creating entirely new medicines, which is a far more expensive and time-consuming path requiring a very different kind of investment, and the company also had significant debt to deal with. So it chose to separate the API business and list it on the stock exchange as a standalone company. Once free to run itself, GLS quickly found external clients and today only 30% of its revenues come from Glenmark Pharma, meaning Nirma is buying a business that has already proven it can stand on its own feet.
The Risk Nirma Is Taking
Nirma has tried to diversify before, and the track record is mixed at best. In 2004, Karsanbhai Patel’s company bought an ailing pharmaceutical firm called Core Healthcare, which made IV fluids, hoping to apply the same low-cost pricing strategy that had made Nirma detergent such a success. But pharma turned out to be a different game entirely, other small players matched Core’s prices, quality concerns crept in, and Nirma could not turn the business around. Then in 2016, Nirma paid around 9,000 crores to buy the Indian operations of the cement giant Lafarge, and later picked up Emami’s cement division too, creating a business called Nuvoco Vistas that became the fifth-largest cement maker in the country. That bet has not delivered the hoped-for results, with the Nuvoco Vistas stock down roughly 30% since it listed on the markets. The question many investors are asking is whether GLS is genuinely different from those earlier experiments, or whether history is about to repeat itself.
What the CDMO Business Could Mean
One area where GLS could create significant new value is in the CDMO space, which stands for Contract Development and Manufacturing Organisation. A CDMO acts as a full-service partner to large pharma companies, handling everything from formulation development to clinical trial support to packaging and supply chain management. Going into all the technical details of how a CDMO operates is outside the scope of this post, but the key point is that this kind of business earns far higher margins than simply supplying raw APIs, because the client is paying for expertise and reliability rather than just a commodity. GLS has flagged this segment as a major growth priority in its annual reports. If Nirma can bring the capital and stability needed to build that side of the business out properly, it could change the financial profile of GLS entirely.
Final Thoughts
Nirma’s move into Glenmark Life Sciences is a bet that the strengths which made a cheap detergent into a household name, namely cost discipline and a willingness to serve markets that others overlook, can translate into pharma. GLS is a genuinely strong business with solid margins, real global market share, and a government tailwind working in its favour. Whether Nirma can sustain and grow that without repeating its earlier stumbles at Core Healthcare or Nuvoco Vistas is the question that will define this chapter of Karsanbhai Patel’s remarkable business journey. For anyone learning how capital markets and corporate strategy work, this story is a useful reminder that buying a good business is only half the equation, and making it better is the part that actually counts.